Novartis: exceeds estimates in Q4
(CercleFinance.com) - The Novartis stock is up 2.
5% today, currently leading Zurich's SMI index, in demand following the publication of Q4 2017 adjusted (core) EPS that is up 8% at 1.21 dollar, beating the consensus by two cents.
The Swiss health giant saw its net sales rise by 5% (+2% in local currencies) to over 12.9 billion dollars, with its core operating income up 7% to over 3.2 billion dollars, also exceeding analysts' forecasts.
For 2018, it expects net sales to increase at a single-digit rate (at constant currencies) between the bottom and middle of the range, with single-digit growth in its core operating income (at constant currencies) between the middle and top of the range.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
5% today, currently leading Zurich's SMI index, in demand following the publication of Q4 2017 adjusted (core) EPS that is up 8% at 1.21 dollar, beating the consensus by two cents.
The Swiss health giant saw its net sales rise by 5% (+2% in local currencies) to over 12.9 billion dollars, with its core operating income up 7% to over 3.2 billion dollars, also exceeding analysts' forecasts.
For 2018, it expects net sales to increase at a single-digit rate (at constant currencies) between the bottom and middle of the range, with single-digit growth in its core operating income (at constant currencies) between the middle and top of the range.
Copyright (c) 2018 CercleFinance.com. All rights reserved.